星空体育官方入口网站网址大全-登录入口官网

#BCL-2#

29篇内容 | 1156人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1707339, encodeId=12f91e0733929, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=Leuk Res：高 Bax/Bcl-2 比值与 B 细胞慢性淋巴细胞白血病患者的良好预后和更好的生存率相关, objectType=article, longId=293668, objectId=78f02936684d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78f02936684d, replyNumber=0, likeNumber=53, createdTime=2022-05-17, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78f02936684d, moduleTitle=Leuk Res：高 Bax/Bcl-2 比值与 B 细胞慢性淋巴细胞白血病患者的良好预后和更好的生存率相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=78f02936684d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707338, encodeId=15b01e0733851, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限, objectType=article, longId=212474, objectId=868f2124e4b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=868f2124e4b8, replyNumber=0, likeNumber=55, createdTime=2022-01-12, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=868f2124e4b8, moduleTitle=亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=868f2124e4b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707336, encodeId=0b771e073360e, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）, objectType=article, longId=206517, objectId=375420651efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=375420651efe, replyNumber=0, likeNumber=44, createdTime=2021-10-27, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=375420651efe, moduleTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=375420651efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707337, encodeId=c88f1e0733738, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=Clin Cancer Res：前列腺癌中恩杂鲁胺耐药性的出现与BCL-2和IKKB依赖性有关, objectType=article, longId=207807, objectId=ba5a20e807a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba5a20e807a7, replyNumber=0, likeNumber=72, createdTime=2021-09-30, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba5a20e807a7, moduleTitle=Clin Cancer Res：前列腺癌中恩杂鲁胺耐药性的出现与BCL-2和IKKB依赖性有关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ba5a20e807a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707328, encodeId=6d511e0732847, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤, objectType=article, longId=196296, objectId=7b82196296b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b82196296b4, replyNumber=0, likeNumber=53, createdTime=2020-09-29, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b82196296b4, moduleTitle=Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7b82196296b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707326, encodeId=dd5c1e073268a, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤, objectType=article, longId=193383, objectId=4d63193383b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d63193383b1, replyNumber=0, likeNumber=61, createdTime=2020-05-05, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d63193383b1, moduleTitle=FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4d63193383b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707330, encodeId=922e1e0733020, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=亚盛医药获得FDA授予第二个孤儿药称号：Bcl-2抑制剂APG-2575治疗华氏巨球蛋白血症, objectType=article, longId=197635, objectId=8f5319e6350c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f5319e6350c, replyNumber=0, likeNumber=99, createdTime=2020-11-02, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f5319e6350c, moduleTitle=亚盛医药获得FDA授予第二个孤儿药称号：Bcl-2抑制剂APG-2575治疗华氏巨球蛋白血症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8f5319e6350c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707332, encodeId=a7931e073322d, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病, objectType=article, longId=200423, objectId=5feb2004238f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5feb2004238f, replyNumber=0, likeNumber=46, createdTime=2021-03-13, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5feb2004238f, moduleTitle=亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5feb2004238f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707334, encodeId=df4e1e07334db, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=Eur Urol：紫杉烷抑制CXCR2/BCL-2途径能够使前列腺癌对铂类治疗敏感, objectType=article, longId=203546, objectId=94d1203546ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94d1203546ae, replyNumber=0, likeNumber=82, createdTime=2021-05-20, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94d1203546ae, moduleTitle=Eur Urol：紫杉烷抑制CXCR2/BCL-2途径能够使前列腺癌对铂类治疗敏感, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=94d1203546ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707331, encodeId=9bc51e0733195, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病, objectType=article, longId=200404, objectId=d860200404a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d860200404a6, replyNumber=0, likeNumber=48, createdTime=2021-02-26, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d860200404a6, moduleTitle=FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d860200404a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707335, encodeId=fc211e07335f3, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=全球上市BCL-2抑制剂维奈克拉在华获批, objectType=article, longId=204278, objectId=7b322042e8be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b322042e8be, replyNumber=0, likeNumber=54, createdTime=2021-06-18, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b322042e8be, moduleTitle=全球上市BCL-2抑制剂维奈克拉在华获批, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7b322042e8be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707333, encodeId=3a991e0733373, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）, objectType=article, longId=202283, objectId=d69920228334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d69920228334, replyNumber=0, likeNumber=65, createdTime=2021-06-22, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d69920228334, moduleTitle=BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d69920228334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707329, encodeId=49aa1e07329e9, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=Blood：Bcl-2成员表达变化揭示了CLL维奈托克耐药机制, objectType=article, longId=197073, objectId=862719e073d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=862719e073d8, replyNumber=0, likeNumber=55, createdTime=2020-07-20, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=862719e073d8, moduleTitle=Blood：Bcl-2成员表达变化揭示了CLL维奈托克耐药机制, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=862719e073d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707324, encodeId=c7ae1e07324f8, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, objectType=article, longId=190017, objectId=0f0519001e6d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0519001e6d, replyNumber=0, likeNumber=65, createdTime=2020-03-26, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0519001e6d, moduleTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0f0519001e6d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准, objectType=article, longId=191730, objectId=1f9c191e301a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f9c191e301a, replyNumber=0, likeNumber=70, createdTime=2020-11-03, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f9c191e301a, moduleTitle=亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1f9c191e301a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707327, encodeId=8e991e0732737, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, objectType=article, longId=193606, objectId=c7931936061f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7931936061f, replyNumber=0, likeNumber=55, createdTime=2021-02-14, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7931936061f, moduleTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c7931936061f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707323, encodeId=5c6f1e073238c, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, objectType=article, longId=187245, objectId=3b7518e245e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b7518e245e4, replyNumber=0, likeNumber=72, createdTime=2020-05-31, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b7518e245e4, moduleTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3b7518e245e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707321, encodeId=4e251e0732168, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=2019 ASCO：AbbVie/Roche发表其BCL-2蛋白抑制剂Venclyxto治疗白血病的阳性数据, objectType=article, longId=167754, objectId=98e616e75482, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98e616e75482, replyNumber=0, likeNumber=58, createdTime=2020-03-02, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98e616e75482, moduleTitle=2019 ASCO：AbbVie/Roche发表其BCL-2蛋白抑制剂Venclyxto治疗白血病的阳性数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=98e616e75482)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707322, encodeId=587e1e073225d, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=进入临床的国产Bcl-2选择性抑制剂！亚盛医药1类新药中国临床完成首例患者给药, objectType=article, longId=175528, objectId=64901e5528d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64901e5528d0, replyNumber=0, likeNumber=64, createdTime=2020-01-02, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64901e5528d0, moduleTitle=进入临床的国产Bcl-2选择性抑制剂！亚盛医药1类新药中国临床完成首例患者给药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=64901e5528d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707318, encodeId=0ff51e0731850, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, objectTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, objectType=article, longId=149701, objectId=7340149e01c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7340149e01c4, replyNumber=0, likeNumber=59, createdTime=2019-02-23, rootId=0, userName=ms3323097325231039, userId=e84031401266, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7340149e01c4, moduleTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7340149e01c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BCL-2

2020-05-29

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

Leuk Res：高 Bax/Bcl-2 比值与 B 细胞慢性淋巴细胞白血病患者的良好预后和更好的生存率相关

2022-05-17

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限

2022-01-12

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）

2021-10-27

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

Clin Cancer Res：前列腺癌中恩杂鲁胺耐药性的出现与BCL-2和IKKB依赖性有关

2021-09-30

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤

2020-09-29

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤

2020-05-05

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

亚盛医药获得FDA授予第二个孤儿药称号：Bcl-2抑制剂APG-2575治疗华氏巨球蛋白血症

2020-11-02

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病

2021-03-13

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

Eur Urol：紫杉烷抑制CXCR2/BCL-2途径能够使前列腺癌对铂类治疗敏感

2021-05-20

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病

2021-02-26

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

全球上市BCL-2抑制剂维奈克拉在华获批

2021-06-18

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）

2021-06-22

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

Blood：Bcl-2成员表达变化揭示了CLL维奈托克耐药机制

2020-07-20

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病

2020-03-26

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准

2020-11-03

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者

2021-02-14

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价

2020-05-31

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

2019 ASCO：AbbVie/Roche发表其BCL-2蛋白抑制剂Venclyxto治疗白血病的阳性数据

2020-03-02

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

进入临床的国产Bcl-2选择性抑制剂！亚盛医药1类新药中国临床完成首例患者给药

2020-01-02

ms3323097325231039 (审核中...)

前往app查看评论内容

#BCL-2#

AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者

2019-02-23

科室
- - 订阅+
  - 更多科室
工具
服务